$2.06
1.48% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US23666P1012
Symbol
DARE

Dare Bioscience, Inc. Stock price

$2.06
-0.33 13.81% 1M
-0.99 32.46% 6M
-1.06 33.97% YTD
-1.54 42.78% 1Y
-11.26 84.53% 3Y
-10.66 83.81% 5Y
-501.94 99.59% 10Y
-819.94 99.75% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.03 1.48%
ISIN
US23666P1012
Symbol
DARE
Industry

Key metrics

Basic
Market capitalization
$27.4m
Enterprise Value
$29.4m
Net debt
$2.0m
Cash
$5.0m
Shares outstanding
9.0m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | 3.7
EV/Sales
- | 4.0
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-27.2%
Return on Equity
67.4%
ROCE
-
ROIC
-
Debt/Equity
-0.6
Financials (TTM | estimate)
Revenue
- | $7.3m
EBITDA
- | -
EBIT
- | $-22.9m
Net Income
- | $-18.3m
Free Cash Flow
$-11.9m
Growth (TTM | estimate)
Revenue
- | 73,170.0%
EBITDA
- | -
EBIT
- | 2.3%
Net Income
- | -351.4%
Free Cash Flow
-8.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -249.5%
Free Cash Flow
-
More
EPS
-
FCF per Share
$-1.3
Short interest
2.0%
Employees
22
Rev per Employee
$0.0
Show more

Is Dare Bioscience, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Dare Bioscience, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Dare Bioscience, Inc. forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Dare Bioscience, Inc. forecast:

Buy
80%
Hold
20%

Financial data from Dare Bioscience, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.09 0.09
97% 97%
100%
- Direct Costs -0.01 -0.01
200% 200%
-11%
0.10 0.10
-
111%
- Selling and Administrative Expenses 8.87 8.87
23% 23%
9,856%
- Research and Development Expense 13 13
34% 34%
14,633%
-1.44 -1.44
95% 95%
-1,600%
- Depreciation and Amortization 0.19 0.19
375% 375%
211%
EBIT (Operating Income) EBIT -1.63 -1.63
94% 94%
-1,812%
Net Profit -1.68 -1.68
94% 94%
-1,867%

In millions USD.

Don't miss a Thing! We will send you all news about Dare Bioscience, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dare Bioscience, Inc. Stock News

Neutral
Seeking Alpha
20 days ago
Daré Bioscience, Inc. (NASDAQ:DARE ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants MarDee J. Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - CEO, President, Principal Financial Officer, Secretary & Director Operator Welcome to the conference call hosted by Daré Bioscience Therapeutics Company's Second Quarter 2025 Financial Results and to p...
Neutral
GlobeNewsWire
20 days ago
DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025
Neutral
GlobeNewsWire
28 days ago
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 14, 2025, to review its financial results for the quarter ended June 30, 2025 and to provide ...
More Dare Bioscience, Inc. News

Company Profile

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Head office United States
CEO Sabrina Johnson
Employees 22
Founded 2015
Website www.darebioscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today